


# 2026 ACCP Annual Meeting

*"Harnessing Changing Clinical Pharmacology Paradigms  
to Improve Patient Outcomes"*

September 27 – 29, 2026 • N Bethesda, Maryland



## 2026 Roger Jelliffe Individualized Therapy Award

### **Edmund Capparelli, PharmD**

Professor of Clinical Pharmacology

Univ of California San Diego

Dr. Edmund Capparelli received his PharmD training at the Univ of California San Francisco, followed by fellowships at Hartford Hosp in Connecticut and at Univ of California Irvine. He is currently a Professor of Clinical Pediatrics & Pharmacy at the Univ of California San Diego in the Div of Host-Microbe Systems & Therapeutics.

Dr. Capparelli has 35 years of experience using population pharmacokinetic (PK) and pharmacodynamic methods to optimize drug therapy in special populations. He serves as the Clinical Pharmacologist for the National Inst of Health Vaccine Research Ctr (VRC), was the Director for the National Inst of Child Health & Development supported Ctr in Research in Pediatric and Development Pharmacology (RPDP) and Specialized HIV Antiretroviral Pharmacology Laboratory and Pharmacometrics Core within the Infant Maternal Pediatric & Adolescent AIDS Trials (IMPAACT) Network. Dr. Capparelli has also served on WHO Pediatric Antiretroviral Working Group, AIDSinfo Pediatric HIV Treatment Guidelines Committee, and Advisory Committees to the US Food & Drug Administration, Ctrs for Disease Control and European Medicines Agency.

Dr. Capparelli has over 300 publications with the majority relating to clinical pharmacology and optimization of anti-infective therapy in special populations including pregnant women and pediatric patients. His studies have included concentration-controlled trial designs, pharmacogenomic dosing, and real time PK with therapeutic drug monitoring (TDM) in various populations including preterm infants. He has developed drug blood spot ARV assays to enable real time TDM optimization of infant therapy within the context of clinical trials. He helped design and served as protocol pharmacologist for IMPAACT studies 1026S and 2026 which enrolled over 1,000 pregnant patients and is arguably the largest PK ever conducted in pregnant persons. It included real time PK for therapeutic drug monitoring and has generated over 40 publications to date.